文献速递前列腺癌

雄激素非依赖性前列腺癌管理的临床考量

Clinical considerations for the management of androgen indifferent prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-02-10

本文综述了雄激素非依赖性前列腺癌(AIPC)变异型,包括侵袭性变异型前列腺癌(AVPC)、神经内分泌前列腺癌(NEPC)和双阴性前列腺癌(DNPC)的临床、形态学和分子特征及当前治疗策略。文章指出,建立共识定义、开发新型生物标志物以实现早期准确检测、进一步表征各表型的分子驱动因素以及开发有效疗法,对于改善AIPC患者的预后至关重要。

要点

  • AIPC变异型(AVPC、NEPC、DNPC)在转移性去势抵抗性前列腺癌接受雄激素受体信号抑制剂治疗后日益常见且常重叠。
  • AIPC与不良预后相关,理解其生物学并识别有效疗法对提高生存至关重要。
  • 游离DNA、循环肿瘤细胞和分子影像等新型诊断方法有望在临床实践中检测AIPC。

核心结论

  • 建立共识定义、开发新型生物标志物、进一步表征分子驱动因素及开发有效疗法对改善AIPC患者预后至关重要。

研究设计与样本

  • 本文为综述,总结了关于AIPC变异型的当前知识,包括临床、形态学和分子特征以及当前治疗方法和新兴疗法与生物标志物。

主要发现

  • 在定义AVPC、NEPC和DNPC的临床和分子特征方面已取得显著进展。
  • 游离DNA、循环肿瘤细胞和分子影像等新型诊断方法是有前景的检测AIPC的工具。
  • 多项临床试验正在基于变异特异性生物学评估AIPC患者的新型治疗方法。

临床怎么用

  • 临床中可考虑使用游离DNA、循环肿瘤细胞和分子影像等新型诊断方法检测AIPC。
  • 基于变异特异性生物学理解,参与评估新型治疗方法的临床试验。

局限性

  • 需要建立共识定义、开发新型生物标志物以实现早期准确检测,并进一步表征各表型的分子驱动因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many systemic therapies for advanced prostate cancer work by disrupting androgen receptor signaling. Androgen indifferent prostate cancer (AIPC) variants, including aggressive variant prostate cancer (AVPC), neuroendocrine prostate cancer (NEPC), and double-negative prostate cancer (DNPC), are increasingly common and often overlapping resistance phenotypes following treatment with androgen receptor signaling inhibitors in men with metastatic castration-resistant prostate cancer and are associated with poor outcomes. Understanding the underlying biology and identifying effective therapies for AIPC is paramount for improving survival for men with prostate cancer. METHODS: In this review, we summarize the current knowledge on AIPC variants, including our current understanding of the clinical, morphologic, and molecular features as well as current therapeutic approaches. We also explore emerging therapies and biomarkers aimed at improving outcomes for men with AIPC. RESULTS AND CONCLUSIONS: Establishing consensus definitions, developing novel biomarkers for early and accurate detection, further characterization of molecular drivers of each phenotype, and developing effective therapies will be critical to improving outcomes for men with AIPC. Significant progress has been made toward defining the clinical and molecular characteristics of AVPC, NEPC, and DNPC. Novel diagnostic approaches, including cell-free DNA, circulating tumor cells, and molecular imaging are promising tools for detecting AIPC in clinical practice. Building on previous treatment advances, several clinical trials are underway evaluating novel therapeutic approaches in patients with AIPC informed by an understanding of variant-specific biology. In this review, we discuss how these recent and ongoing studies will help to improve diagnosis, prognosis, and therapy for men with AIPC.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Berchuck JE, Viscuse PV, Beltran H, et al. Clinical considerations for the management of androgen indifferent prostate cancer. Prostate Cancer Prostatic Dis. 2021. PMID: 33568748. doi:10.1038/s41391-021-00332-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。